Infertility: How can the ovulation function be restored?

One of the most frequent is the existence of tumours that induce an over-secretion of this hormone. These women present with chronic infertility due to anovulation. Thanks to the work of the Inserm researchers from unit 693 "Steroid receptors: endocrinian and metabolic physiopathology", the intimate mechanism of the hyperprolactinaemia alterations affecting reproduction in mice has been discovered.

This work has been published in the journal JCI.

Hyperprolactinaemia is a major cause of anovulation and is responsible for menstruation disorders and infertility. However, not much was know in detail of the mechanisms that cause this pathology. All that was known was that an increase in in women disturbed one of the most important hormones affecting reproduction and fertility: GnRH .

Up until now, we had been unable to understand this of prolactin in the GnRH neurons, because most of these neurons did not express the prolactin receptor.

So the researchers put forward another hypothesis: what if it was due to the indirect action of other molecules?

The team led by Jacques Young and Nadine Binart from Inserm unit 693 ": endocrinian and metabolic physiopathology" at the Bicêtre hospital, discovered that prolactin had an indirect effect on GnRH. Using mice as models, they demonstrated that prolactin effectively inhibits the secretion of neurons situated upstream the GnRH neurons and that are essential to their functioning. They secrete a neurohormone known as kisspeptin.

Kisspeptin: the key to infertility?

In mice, hyperprolactinaemia directly inhibits the secretion of kisspeptin and by preventing the of GnRH, effectively blocks ovarian cyclicity. By administering kisspeptin, we can restore the release of GnRH and restart ovarian cyclic functioning and ovulation despite hyperprolactinaemia.

The effect of hyperprolactinaemia on the ovulation cycle (credit: J Young/Inserm)

This is both a physiopathological discovery that for the first time explains the link between and hyperprolactinaemia, and a new approach opening the way to an original therapy. On-going studies are aiming to validate the concept in women, so that we can provide a therapeutic alternative when the subject is resistant to the available medication.

More information: Hyperprolactinaemia-induced ovarian acyclicity is reversed by kisspeptin administration, JCI, 2012.

add to favorites email to friend print save as pdf

Related Stories

Hormone offers promise as fertility treatment

Mar 16, 2009

New research suggests the hormone kisspeptin shows promise as a potential new treatment for infertility. The research is being presented at the annual Society for Endocrinology BES meeting in Harrogate. Scientists led by ...

A missing link from obesity to infertility found

Sep 07, 2010

Obese women have a well-known risk for infertility, but a new Johns Hopkins Children's Center study has unraveled what investigators there believe is the mechanism that accounts for the risk.

Recommended for you

Biomedical team creates 'nerve on a chip'

Dec 24, 2014

Michael J. Moore and J. Lowry Curley first met in the laboratory as professor and student. Now the two Tulane University researchers have started a new biomedical company that's winning praise and awards.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.